Pilot study of topical trifluridine for the treatment of acyclovir-resistant mucocutaneous herpes simplex disease in patients with AIDS (ACTG 172)

An open label pilot study involving 26 AIDS patients was conducted to evaluate the efficacy and toxicity of topical 1% ophthalmic trifluridine solution for the treatment of chronic mucocutaneous herpes simplex virus disease unresponsive to at least ten days of acyclovir therapy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 1996-06, Vol.12 (2), p.147-152
Hauptverfasser:	KESSLER, H. A, HURWITZ, S, MCKINLEY, G. F, WETTLAUFER, B, OWENS, S, NEVIN, T, KORVICK, J. A, FARTHING, C, BENSON, C. A, FEINBERG, J, KURITZKES, D. R, BAILEY, T. C, SAFRIN, S, STEIGBIGEL, R. T, CHEESEMAN, H
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome AIDS Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Biological and medical sciences Drug therapy herpes simplex virus Herpes viruses Medical research Medical sciences Pharmacology. Drug treatments
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	An open label pilot study involving 26 AIDS patients was conducted to evaluate the efficacy and toxicity of topical 1% ophthalmic trifluridine solution for the treatment of chronic mucocutaneous herpes simplex virus disease unresponsive to at least ten days of acyclovir therapy.
ISSN:	1077-9450 1525-4135 2331-6993 1944-7884
DOI:	10.1097/00042560-199606010-00007